Supplementary Figure 2 from Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Ron Bose,Shyam M. Kavuri,Adam C. Searleman,Wei Shen,Shen Dong,Daniel C. Koboldt,John Monsey,Nicholas Goel,Adam B. Aronson,Shunqiang Li,X. Cynthia,Li Ding,Elaine R. Mardis,Matthew J. Ellis

DOI: https://doi.org/10.1158/2159-8290.22528739

2023-01-01

Abstract:PDF file - 86K, Flow cytometry measurements of cell-surface expression of HER2 mutants

What problem does this paper attempt to address?

Supplementary Figure 7 from Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Ron Bose,Shyam M. Kavuri,Adam C. Searleman,Wei Shen,Shen Dong,Daniel C. Koboldt,John Monsey,Nicholas Goel,Adam B. Aronson,Shunqiang Li,X. Cynthia,Li Ding,Elaine R. Mardis,Matthew J. Ellis

DOI: https://doi.org/10.1158/2159-8290.22528724.v1

2023-01-01

Abstract:PDF file - 106K, Protein structure modeling suggests that HER2 D769 is located near the HER2-HER3 kinase domain dimer interface
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Wen‐Jia Zuo,Yi‐Zhou Jiang,Yujie Wang,Xiao‐En Xu,Xin Hu,Guangyu Li,Jiong Wu,Gen-Hong Di,Ke‐Da Yu,Zhi‐Ming Shao

DOI: https://doi.org/10.1158/1078-0432.22467669

2023-01-01

Abstract:Supplementary Figure S1. Flowchart of study design. Supplementary Figure S2. Protein structure visualizations of the HER2 somatic mutations. Supplementary Figure S3. HER2 mutations L768S and V773L induce HER2 internalization. Supplementary Figure S4. Kaplan-Meier estimates of relapse-free survival (RFS) according to HER2 mutation in different regions.
Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced let-7g Expression in Breast Cancer Invasion and Metastasis

Pengxu Qian,Zehua Zuo,Zhengsheng Wu,Xianyi Meng,Gaopeng Li,Zhengzhou Wu,Weijie Zhang,Sheng Tan,Vijay Pandey,Yandan Yao,Puyue Wang,Liqing Zhao,Jun Wang,Qiang Wu,Erwei Song,Peter E. Lobie,Zhinan Yin,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.22391054

2023-01-01

Abstract:PDF file - 214K
Supplementary Figure 2 from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388201.v1

2023-01-01

Abstract:PDF file - 256K
Supplementary Figure 4 from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388195

2023-01-01

Abstract:PDF file - 205K
Supplementary Figure 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Yan Lu,Ming You,Zara Ghazoui,Pengyuan Liu,Peter T. Vedell,Weidong Wen,Ann M. Bode,Clinton J. Grubbs,Ronald A. Lubet

DOI: https://doi.org/10.1158/1940-6207.22524291

2023-01-01

Abstract:PDF file - 322K, Gene Expression Changes Comparing Control Breast Cancer and Breast Cancers Treated with an Aromatase Inhibitor in Humans (GSE 16391)
Supplementary Figure 3 from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388198.v1

2023-01-01

Abstract:PDF file - 260K
Supplementary Figure 1 from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388204

2023-01-01

Abstract:PDF file - 206K
Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of her2 Mutations in her2 Nonamplified Metastatic Breast Cancer

X. Cynthia,Ron Bose,Feng Gao,Rachel A. Freedman,Melinda L. Telli,Gretchen Kimmick,Eric P. Winer,Michael Naughton,Matthew P. Goetz,Christy Russell,Debu Tripathy,Melody Cobleigh,Andres Forero,Timothy Pluard,Carey K. Anders,Polly Niravath,Shana Thomas,Jill Anderson,Caroline Bumb,Kimberly C. Banks,Richard B. Lanman,Richard Bryce,Alshad S. Lalani,John D. Pfeifer,Daniel F. Hayes,Mark D. Pegram,Kimberly Blackwell,Philippe L. Bédard,Hussam Al‐Kateb,Matthew J. Ellis

DOI: https://doi.org/10.1158/1078-0432.22467027

2023-01-01

Abstract:Supplementary Figures S1, S2, S3 and Tables S1, S2
Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497787

2023-01-01

Abstract:PDF file - 63K, Figure S1: Expression of RON and MET by breast cancer MCF-7, T-47D and ZR-75-1 cells.
Supplementary Figure Legends 1-4, Methods from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388192

2023-01-01

Abstract:Supplementary Figure Legends 1-4, Methods from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Figure 5 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Yong-Jian Deng,Na Tang,Chao Liu,Jiang-Yu Zhang,Sheng-Li An,Yin-Li Peng,Li-Li Ma,Guang-Qiu Li,Qiang Jiang,Chun-Ting Hu,Ya-Nan Wang,Yao-Ze Liang,Xiu-Wu Bian,Wei-Gang Fang,Yan-Qing Ding

DOI: https://doi.org/10.1158/1078-0432.22445468.v1

2023-01-01

Abstract:PDF file - 2897K, Stemness of cancer stem-like cells related to ERp29, CLIC4 and Smac.
Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Yan Lu,Ming You,Zara Ghazoui,Pengyuan Liu,Peter T. Vedell,Weidong Wen,Ann M. Bode,Clinton J. Grubbs,Ronald A. Lubet

DOI: https://doi.org/10.1158/1940-6207.22524288

2023-01-01

Abstract:PDF file - 36K
Supplementary Figure 2 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Yong-Jian Deng,Na Tang,Chao Liu,Jiang-Yu Zhang,Sheng-Li An,Yin-Li Peng,Li-Li Ma,Guang-Qiu Li,Qiang Jiang,Chun-Ting Hu,Ya-Nan Wang,Yao-Ze Liang,Xiu-Wu Bian,Wei-Gang Fang,Yan-Qing Ding

DOI: https://doi.org/10.1158/1078-0432.22445477.v1

2023-01-01

Abstract:PDF file - 45K, Identifying cancer stem-like cells characteristics of tumor spheres.
Supplementary Figure 2 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446039.v1

2023-01-01

Abstract:PDF file - 1452K, Figure S2. Genetic mutations in exon 14 of PDGFRA.

Supplementary Figure 2 from Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Supplementary Figure 7 from Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure 2 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 4 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Figure 3 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of <i>her2</i> Mutations in <i>her2</i> Nonamplified Metastatic Breast Cancer

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure Legends 1-4, Methods from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure 5 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Figure 2 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Supplementary Figure 7 from Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced &lt;i&gt;let-7g&lt;/i&gt; Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure 2 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 4 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Figure 3 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of &lt;i&gt;her2&lt;/i&gt; Mutations in &lt;i&gt;her2&lt;/i&gt; Nonamplified Metastatic Breast Cancer

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure Legends 1-4, Methods from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure 5 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER&lt;sup&gt;+&lt;/sup&gt; Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Figure 2 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Supplementary Figure 2 from Large-scale Analysis of &lt;i&gt;pdgfra&lt;/i&gt; Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure 2 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 4 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 3 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of <i>her2</i> Mutations in <i>her2</i> Nonamplified Metastatic Breast Cancer

Supplementary Figure Legends 1-4, Methods from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib